Table 2.
Baseline | Acute PCP study | Chronic PCP study | |||||
---|---|---|---|---|---|---|---|
WT | NTS1 −/− | AP-WT | AP-NTS1−/− | CP-WT | CP-NTS1−/− | ||
Behavioral tests | Locomotor activity | +++ | +++ | ++ | ++ | ||
FST | +++ | N/A | N/A | +++ | +++ | ||
TST | +++ | N/A | N/A | +++ | +++ | ||
Microdialysis | DA | +++ | − − − | ||||
Glu | − − − | +++ | − − | − − | |||
mRNA | DA D1 | − − − | N/A | N/A | − − − | − − | |
DA D2 | − − − | N/A | N/A | − − − | − − − | ||
TH | N/A | N/A | |||||
NMDAR1 | N/A | N/A | ++ | ||||
NMDAR2A | − − − | N/A | N/A | − − − | − − − | ||
Binding assay | DA D2 | − − − | N/A | N/A | − − − | − − − | |
NMDAR2A | − − − | N/A | N/A | − − − | − − − |
“Grayed-out areas” = No change as compared with WT baseline
“+++” = large increase
“++” = moderate increase
“−−−” = large decrease
“−−” = moderate decrease N/A= not tested